Biotech Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio

Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences.

Nearly three years after its initial $53 million series A, Senti Bio now has now doubled its funding, adding Bayer’s VC arm into the mix and continuing in 2021 its ongoing mission to become a broad gene therapy player.